This indefinite delivery contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC), National Center for Immunization and Respiratory Diseases (NCIRD) to Grifols USA LLC, a global healthcare company and manufacturer of essential plasma-derived medicines and vaccines. The contract, valued at a ceiling of $12,409,500, is for the supply of 20 standard pediatric vaccines to support immunization programs under the Vaccines for Children (VFC) program and Section 317(j) of the Public Health Service Act. The period of performance is April 1, 2021 through March 31, 2022, and the vaccines must have a minimum 12-month shelf life.
The vaccines to be provided include DTaP, DTaP/HepB/IPV, DTaP-IPV, DTaP-IP-Hib, IPV, pediatric Hepatitis A and B, Hib, HPV, MMR, MCV4, pneumococcal conjugate and polysaccharide, rotavirus, Td, Tdap, varicella, and MMRV. Estimated quantities range from a minimum of 100 doses to a maximum of 13 million doses, depending on the vaccine type. The vaccines will be shipped F.O.B. Destination to the 50 states and U.S. territories, and the acquisition will be conducted in accordance with FAR Part 12 for commercial items. This IDC allows the CDC to competitively order vital pediatric vaccines through task orders without conducting repetitive solicitations.
Generated 6/30/24, 9:06 AM